Literature DB >> 564762

Parathyrin radioimmunoassay: diagnostic utility of antisera produced against carboxyl-terminal fragments of the hormone from the human.

F P Di Bella, J M Kehrwald, K Laakso, L Zitzner.   

Abstract

Antisera directed toward the carboxyl-terminal region of human parathyrin (parathyroid hormone), for use in daignostically applicable radioimmunoassays of the hormone in serum, are scarce, largely because of the lack of suitable immunogens of human origin. We produced four antisera in goats and guinea pigs by immunization with recently discovered carboxyl-terminal fragments of human parathyrin extracted from parathyroid tumors. Here, we report results of radioimmunoassays of nearly 200 normal and pathological sera with one of these antisera; we observed almost complete differentiation between concentrations of parathyrin in serum of healthy normal subjects and patients with primary, secondary (due to chronic renal failure), or "ectopic" hyperparathyroidism (due to nonparathyroid cancer). The availability of a new immunogen should now make possible the deliberate production of large quantities of diagnostically applicable parathyrin antisera directed toward the carboxyl-terminal region of human parathyrin. This should, in turn, lead to more widespread availability of this useful radioimmunoassay.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 564762

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  2 in total

1.  Differentiation of hypercalcaemia due to malignancy from primary hyperparathyroidism: the value of parathyroid hormone and plasma bicarbonate measurements.

Authors:  R Freaney; E Ryan; F P Muldowney
Journal:  Ir J Med Sci       Date:  1981-01       Impact factor: 1.568

2.  Development of a highly sensitive and specific two-site enzyme immunoassay for parathyroid hormone (1-34): application to pharmacokinetic study on intranasal parathyroid hormone (1-34) in human.

Authors:  T Kohno; N Murasugi; H Sakurai; K Watabe; H Nakamuta; M Koida; Y Sugie; M Nomura; A Yanagawa
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.